NBI-921352
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Trial Timeline
Jul 12, 2022 → Mar 1, 2026
NCT ID
NCT05226780About NBI-921352
NBI-921352 is a phase 2 stage product being developed by Neurocrine Biosciences for SCN8A Developmental and Epileptic Encephalopathy Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05226780. Target conditions include SCN8A Developmental and Epileptic Encephalopathy Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05493293 | Phase 2 | Terminated |
| NCT05226780 | Phase 2 | Active |
Competing Products
1 competing product in SCN8A Developmental and Epileptic Encephalopathy Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NBI-921352 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |